SALT LAKE CITY -- (Business Wire)
BSD Medical Corporation (NASDAQ:BSDM) (the “Company” or “BSD”), a
leading provider of medical systems that treat cancer and benign
diseases using heat therapy, announced today that Drs. JY Gaubert, P
Chevallier, and V Vidal, leading French researchers, presented the
successful results of their animal study utilizing the MicroThermX®
Microwave Ablation System (MicroThermX) at CIRSE 2014. The study was
sponsored by Terumo Europe N.V. The objective of the study was to
determine reproducibility of the ablation volumes in liver and lung
animal studies using the MicroThermX. The researchers examined the
results of 18 liver ablations and 24 lung ablations and concluded that
ablation volumes generated with the MicroThermX were reproducible in
in-vivo liver and lung tissues.
“The positive results of this study reflect BSD’s and Terumo Europe N.V.’s
ongoing, long-term commitment to drive innovation and expand treatment
options for patients,” said Sam Maravich, Vice President of
International Sales and Marketing at BSD Medical. “This study, and
others to follow, could help pave the way for our MicroThermX system to
be adopted by hospitals and treatment centers all over the world.
Microwave ablation therapy has the potential to improve treatment
outcomes and quality of life for patients.”
The study, “In vivo experimental evaluation of ablation volumes obtained
by microwave in the lung and liver with MicroThermX,” was conducted by
the Department of Adult Radiology at Timone University in Marseille,
France; the Department of Radiology at University Hospital L’Archet in
Nice, France; and the Laboratory of Experimental and Interventional
Imagining at Aix-Marseille University, leading research institutions in
France.
About the MicroThermX®Microwave Ablation
System
The MicroThermX is a compact, mobile, state-of-the-art, proprietary
system that includes a microwave generator, single-patient-use
disposable antennas, and a thermistor-based temperature monitoring
system. The innovative design of the MicroThermX is the first of its
kind that allows delivery of higher power levels using a single
generator.
The MicroThermX utilizes innovative synchronous phased array technology
that was developed and patented by MicroThermX BSD to provide a wide
range of uniform zones of ablation. The MicroThermX includes innovative,
high-end disposables (SynchroWave antennas) that are used in each
ablation treatment and will provide a significant ongoing revenue stream.
The U.S. Food and Drug Administration (FDA) has granted the Company a
510(k) clearance to market the MicroThermXfor ablation of
soft tissue. BSD has also received CE Marking for the MicroThermX
System, which allows BSD to market the MicroThermX in Europe. CE Marking
is also recognized in many countries outside of the EU, providing BSD
the ability to market the MicroThermX to a number of international
markets.
About BSD Medical Corporation
BSD Medical Corporation develops, manufactures, markets and services
systems to treat cancer and benign diseases using heat therapy delivered
using focused microwave energy and radiofrequency (RF). BSD’s product
lines include ablation and hyperthermia treatment systems. BSD’s
microwave ablation system has been developed as a stand-alone therapy to
ablate and destroy soft tissue. The Company has developed extensive
intellectual property, multiple products in the market, and well
established distribution in the United States, Europe and Asia. BSD’s
hyperthermia cancer treatment systems, which have been in use for
several years in the United States, Europe and Asia, are used to treat
certain tumors with heat (hyperthermia) while increasing the
effectiveness of other therapies such as radiation therapy. Certain of
the Company’s products have received regulatory approvals in the United
States, Europe and China. For further information visit BSD Medical’s
website at www.BSDMedical.com.
Forward-Looking Statements
Statements contained in this press release that are not historical
facts, including statements relating to our 2015 plans, are
forward-looking statements, as defined in the Private Securities
Litigation Reform Act of 1995. All forward-looking statements are
subject to risks and uncertainties detailed in the Company’s filings
with the Securities and Exchange Commission, including the market demand
for our MicroThermX® products and the regulatory requirements we face.
These forward-looking statements speak only as of the date on which such
statements are made, and the Company undertakes no obligation to update
such statements to reflect events or circumstances arising after such
date, except as required by law.
Contacts:
For BSD Medical Corporation
Tricia Ross, 310-622-8226
investor@bsdmc.com
Source: BSD Medical Corporation
© 2024 Canjex Publishing Ltd. All rights reserved.